The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Plaque Psoriasis: Secukinumab Beats Ustekinumab in a Head-to Head Clinical Trial & Ixekizumab Helps Improve Productivity

Plaque Psoriasis: Secukinumab Beats Ustekinumab in a Head-to Head Clinical Trial & Ixekizumab Helps Improve Productivity

March 23, 2016 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270Secukinumab vs. Ustekinumab for Plaque Psoriasis
In a 52-week clinical trial, secukinumab proved superior to ustekinumab for sustained skin clearance in adults with moderate to severe plaque psoriasis.1 More patients treated with secukinumab achieved a greater than 90% Psoriasis Area and Severity Index (PASI) score than those treated with ustekinumab. The secukinumab PASI 90 response was 76% and the ustekinumab PASI 90 response was 61%. At Week 52, PASI 100 (clear skin) response was also significantly better for secukinumab-treated patients compared with ustekinumab-treated patients (46% vs. 36%).

You Might Also Like
  • Ixekizumab Improves Work Productivity in Patients with Plaque Psoriasis
  • Rheumatology Drug Updates: Ixekizumab Improves Work Productivity, plus Vobarilizumab Completes Phase 2 Trial in Rheumatoid Arthritis
  • U.S. FDA Approves Lilly’s Ixekizumab for Plaque Psoriasis
Also By This Author
  • Upadacitinib + Methotrexate & Other csDMARDs in RA Patients

Additionally, significantly greater and sustained Dermatology Life Quality Index responses were obtained for secukinumab-treated patients compared with ustekinumab-treated patients (72% vs. 59%). Half of secukinumab-treated patients achieved PASI 75 at Week 4 of the study (50% vs. 21%, P<0.0001).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Secukinumab is a fully human interleukin-17A inhibitor that is U.S. Food and Drug Administration approved to treat moderate to severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis.

Ixekizumab Improves Productivity in Patients with Plaque Psoriasis
Ixekizumab, an IgG4 monoclonal antibody, selectively binds with the interleukin-17A (IL-17A) cytokine, inhibiting its interaction with the IL-17 receptor and inhibiting the release of pro-inflammatory cytokines and chemokines. The treatment is being investigated to treat moderate to severe plaque psoriasis and active psoriatic arthritis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The results of three pivotal Phase 3 trials that evaluated work productivity in patients with moderate to severe plaque psoriasis receiving ixekizumab every two weeks were recently reported. These studies are UNCOVER-1, UNCOVER-2 and UNCOVER-3.2

Work productivity, evaluated by the change from baseline as measured by Work Productivity and Activity Impairment-Psoriasis (WPAI-PSO) scores, were evaluated at Week 12 of the studies. Compared with placebo-treated patients, all ixekizumab-treated patients reported improved work productivity. Additionally, in the UNCOVER-1 study, these work productivity improvements were sustained up to 60 weeks in patients who had a clinical response to ixekizumab at Week 12. Also, in UNCOVER-1 and UNCOVER-3, ixekizumab-treated patients had significantly greater improvement in all WPAI-PSO scores (e.g., absenteeism, presenteeism, work productivity loss and activity impairment [P<0.001 for all]) compared with placebo-treated patients. In the UNCOVER-2 study, ixekizumab-treated patients compared with placebo-treated patients showed significantly greater improvement in all WPAI-PSO scores: absenteeism (P=0.016), presenteeism (P<0.001), work productivity loss (P<0.001) and activity impairment (P<0.001).

When ixekizumab-treated patients were compared with etanercept-treated patients, ixekizumab-treated patients also showed significantly greater improvement in WPAI scores for presenteeism, work productivity loss and activity impairment (P< 0.001 for all).

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Treatment-emergent adverse events were mild or moderate, with the most common being reported as injection-site reactions and upper respiratory tract infections, most frequently nasopharyngitis.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: ixekizumab, plaque psoriasis, productivity, secukinumab, skin, ustekinumab, workplace

You Might Also Like:
  • Ixekizumab Improves Work Productivity in Patients with Plaque Psoriasis
  • Rheumatology Drug Updates: Ixekizumab Improves Work Productivity, plus Vobarilizumab Completes Phase 2 Trial in Rheumatoid Arthritis
  • U.S. FDA Approves Lilly’s Ixekizumab for Plaque Psoriasis
  • Ustekinumab Approved for Use in Adolescents with Plaque Psoriasis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)